[ad_1]
Every day there are new reports of promising corona vaccines. The World Health Organization (WHO) currently lists nearly 80 developers of crown vaccines. Although feverish research is underway, experts don’t expect the first widely used vaccine until early 2021 at the earliest.
The American company Moderna began evaluating people in March. Also on board: the Swiss pharmaceutical supplier Lonza. The latter announced an agreement with Moderna last week to produce the corona vaccine. Lonza’s US subsidiary plans to start producing volumes in July.
The two companies plan to produce up to a billion cans. This encourages Lonza’s participation in the stock market. It rose on Monday, in a trade that is otherwise declining. However, no vaccine that has been developed using the Moderna gene-based method has yet to receive approval.
The British are ahead in the race
The vaccine by a research team from Oxford (Great Britain) is considered very promising. He entered the delicate phase of clinical trial two weeks ago. The British use weakened harmless viruses, which disguise themselves as corona viruses, so-called vectors, to trigger an immune response in the body. Janssen Vaccines uses the same method for his corona vaccine.
The method has been shown to be effective on Ebola and HIV. The United States government announced in April that it would invest nearly half a trillion dollars each in the development and production of the Janssen and Moderna crown vaccines.
Chinese research groups are already doing clinical tests. The team of Martin Bachmann (52) from the University of Bern and other universities, as well as the Saiba company, are starting a clinical trial. German company Biontech in cooperation with Pfizer also received the green light for human testing two weeks ago.
